|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Infection with LD100 induced the expression of the following factors: Interleukins (ILs), IL-4, IL-7, IL-10, IL-11, IL-12p40, IL-13 and IL-15; inflammatory chemokines, C-C motif chemokine ligand (CCL)2, CCL3/4, CCL12, CCL17, CCL19; and lung injury-associated cytokines, leptin, leukaemia inhibitory factor, macrophage colony stimulating factor, pentraxin (PTX)2 and PTX3, WNT1-inducible-signaling pathway protein 1, matrix metallopeptidase (MMP)-2, MMP-3, proprotein convertase subtilisin/kexin type 9, and T cell immunoglobulin and mucin domain.
|
31777543 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-2 (IL-2) and IL-15 play pivotal roles in T cell activation, apoptosis, and survival, and are implicated in leukemias and autoimmune diseases.
|
31570576 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To address this shortcoming, leukemia cell lines with NK cell-like function or ex vivo expansion approaches centered on the homeostatic cytokine IL-15 were developed.
|
31355489 |
2019 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Sorafenib-related IL-15 production caused an increase in CD8<sup>+</sup>CD107a<sup>+</sup>IFN-γ<sup>+</sup> T cells with features of longevity (high levels of Bcl-2 and reduced PD-1 levels), which eradicated leukemia in secondary recipients.
|
29431743 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results provided evidence that IL-15 gene-modification could augment NK cell-mediated anti-human leukemia function, which would improve primary NK cell-based immunotherapy for leukemia in future.
|
29737430 |
2018 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, during GVHD, donor T cells compete with NK cells for IL-15 thereby inducing profound defects in NK-cell reconstitution that compromise both leukemia and pathogen-specific immunity.
|
27927647 |
2017 |
|
leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Downregulation of STAT3 phosphorylation enhances tumoricidal effect of IL-15-activated dendritic cell against doxorubicin-resistant lymphoma and leukemia via TNF-α.
|
26255115 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Blockade of IL2 and IL15 using monoclonal antibodies has been reported to be of value in the treatment of patients with leukemia, autoimmune disorders, and in the prevention of allograft rejection.
|
25736261 |
2015 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Development of iCD8α cells depends on expression of interleukin-2 receptor γ chain (IL-2Rγc), IL-15, and the major histocompatibility complex (MHC) class Ib protein H2-T3, also known as the thymus leukemia antigen or TL.
|
25220211 |
2014 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Gene therapy strategies using IL-15 should include a safety mechanism in anticipation of possible adverse effects because IL-15 overexpression has been implicated in autoimmune disorders and may be involved in the pathogenesis of some leukemias.
|
23582229 |
2013 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study provides the first evidence that CIK(IL-15) cells may offer a therapeutic option for patients with refractory or relapsed leukemia following haplo-identical HSCT.
|
21973023 |
2012 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-15 may have a role in the development of T cell large granular lymphocyte (T-LGL) or NKT leukemias.
|
21364281 |
2011 |
|
leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fatal leukemia in interleukin-15 transgenic mice.
|
11358383 |
2001 |